|Description||Psoriasis (PSORS) is a chronic, immune-mediated inflammatory skin disease, characterized by increased propagation of the epidermis with dilation of dermal capillaries. The major symptoms of psoriasis are itchy, scaly, and flaky skin, swelling, pain, and disfiguring skin lesions. Plaque psoriasis is the most common form. Other forms include flexural, guttate, nail, inverse psoriasis, erythroderma, and psoriatic arthritis. Nail psoriasis can accompany any form of psoriasis or occur of its own accord. It can occur in any age group, but psoriatic arthritis usually develops between the ages of 30-50 years. Various factors such as bacterial infection, genetic and environmental factors, and immune disorders play an important role in causing psoriasis. Psoriasis is associated with several comorbidities, including cardiovascular disease, lymphoma, and depression. Psoriasis is an immune-mediated disease with genetic predisposition, but no distinct immunogen has been identified. The presence of cytokines, dendritic cells, and T lymphocytes in psoriatic lesions has prompted the development of biologic therapies. The diagnosis is usually clinical, based on the presence of typical erythematous scaly patches, papules, and plaques that are often pruritic and sometimes painful. Biopsy is rarely needed to confirm the diagnosis. First-line therapies for most patients are topical treatments such as topical corticosteroids and vitamin D analogs. For those with more severe or treatment-resistant disease, second- or third-line therapies include phototherapy, systemic therapies such as methotrexate, and more recently biologic therapies such as tumour necrosis factor (TNF) inhibitors.|
|Category||Skin and connective tissue disease; Immune system disease|
|Gene||(PSORS1) HLA-C [HSA:3107] [KO:K06751]
(PSORS2) CARD14 [HSA:79092] [KO:K20913]
(PSORS13) TRAF3IP2 [HSA:10758] [KO:K21124]
(PSORS14) IL36RN [HSA:26525] [KO:K05483]
(PSORS15) AP1S3 [HSA:130340] [KO:K12395]
|Drug||Dexamethasone sodium phosphate [DR:D00975]
Betamethasone dipropionate [DR:D01637]
Calcipotriol hydrate [DR:D10198]
Calcipotriene and betamethasone dipropionate [DR:D10534]
Halobetasol propionate [DR:D04409]
Clobetasol propionate [DR:D01272]
Cortisone acetate [DR:D00973]
Methotrexate sodium [DR:D02115]
Tofacitinib citrate [DR:D09783]
|Other DBs||ICD-11: EA90
OMIM: 177900 602723 614070 614204 616106
AUTHORS Garg T, Rath G, Goyal AK
TITLE Nanotechnological approaches for the effective management of psoriasis.
JOURNAL Artif Cells Nanomed Biotechnol 44:1374-82 (2016)
AUTHORS Weigle N, McBane S
JOURNAL Am Fam Physician 87:626-33 (2013)
PMID:24350319 (description, drug)
AUTHORS Burfield L, Burden AD
JOURNAL J R Coll Physicians Edinb 43:334-8; quiz 339 (2013)
AUTHORS Lebwohl M, Ting PT, Koo JY
TITLE Psoriasis treatment: traditional therapy.
JOURNAL Ann Rheum Dis 64 Suppl 2:ii83-6 (2005)
AUTHORS Limaye K
TITLE Psoriasis: an overview and update.
JOURNAL Nurse Pract 40:23-6 (2015)
AUTHORS Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, Suomela S, Snellman E, Saarialho-Kere U, Kere J
TITLE A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele.
JOURNAL Hum Mol Genet 9:1533-42 (2000)
AUTHORS Jordan CT, Cao L, Roberson ED, Pierson KC, Yang CF, Joyce CE, Ryan C, Duan S, Helms CA, Liu Y, Chen Y, McBride AA, Hwu WL, Wu JY, Chen YT, Menter A, Goldbach-Mansky R, Lowes MA, Bowcock AM
TITLE PSORS2 is due to mutations in CARD14.
JOURNAL Am J Hum Genet 90:784-95 (2012)
AUTHORS Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, Korendowych E, Juneblad K, Apel M, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Lascorz J, Bohm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Herold C, Steffens M, Klareskog L, Wienker TF, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A
TITLE Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis.
JOURNAL Nat Genet 42:996-9 (2010)
AUTHORS Farooq M, Nakai H, Fujimoto A, Fujikawa H, Matsuyama A, Kariya N, Aizawa A, Fujiwara H, Ito M, Shimomura Y
TITLE Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis.
JOURNAL Hum Mutat 34:176-83 (2013)
AUTHORS Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu HC, Allen MH, Duckworth M, Bachelez H, Burden AD, Choon SE, Griffiths CE, Kirby B, Kolios A, Seyger MM, Prins C, Smahi A, Trembath RC, Fraternali F, Smith CH, Barker JN, Capon F
TITLE AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking.
JOURNAL Am J Hum Genet 94:790-7 (2014)